Development and validation of an artificial intelligence-based model for detecting urothelial carcinoma using urine cytology images: a multicentre, diagnostic study with prospective validation.

IF 9.6 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL
EClinicalMedicine Pub Date : 2024-03-27 eCollection Date: 2024-05-01 DOI:10.1016/j.eclinm.2024.102566
Shaoxu Wu, Runnan Shen, Guibin Hong, Yun Luo, Huan Wan, Jiahao Feng, Zeshi Chen, Fan Jiang, Yun Wang, Chengxiao Liao, Xiaoyang Li, Bohao Liu, Xiaowei Huang, Kai Liu, Ping Qin, Yahui Wang, Ye Xie, Nengtai Ouyang, Jian Huang, Tianxin Lin
{"title":"Development and validation of an artificial intelligence-based model for detecting urothelial carcinoma using urine cytology images: a multicentre, diagnostic study with prospective validation.","authors":"Shaoxu Wu, Runnan Shen, Guibin Hong, Yun Luo, Huan Wan, Jiahao Feng, Zeshi Chen, Fan Jiang, Yun Wang, Chengxiao Liao, Xiaoyang Li, Bohao Liu, Xiaowei Huang, Kai Liu, Ping Qin, Yahui Wang, Ye Xie, Nengtai Ouyang, Jian Huang, Tianxin Lin","doi":"10.1016/j.eclinm.2024.102566","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Urine cytology is an important non-invasive examination for urothelial carcinoma (UC) diagnosis and follow-up. We aimed to explore whether artificial intelligence (AI) can enhance the sensitivity of urine cytology and help avoid unnecessary endoscopy.</p><p><strong>Methods: </strong>In this multicentre diagnostic study, consecutive patients who underwent liquid-based urine cytology examinations at four hospitals in China were included for model development and validation. Patients who declined surgery and lacked associated histopathology results, those diagnosed with rare subtype tumours of the urinary tract, or had low-quality images were excluded from the study. All liquid-based cytology slides were scanned into whole-slide images (WSIs) at 40 × magnification and the WSI-labels were derived from the corresponding histopathology results. The Precision Urine Cytology AI Solution (PUCAS) was composed of three distinct stages (patch extraction, features extraction, and classification diagnosis) and was trained to identify important WSI features associated with UC diagnosis. The diagnostic sensitivity was mainly used to validate the performance of PUCAS in retrospective and prospective validation cohorts. This study is registered with the ChiCTR, ChiCTR2300073192.</p><p><strong>Findings: </strong>Between January 1, 2018 and October 31, 2022, 2641 patients were retrospectively recruited in the training cohort, and 2335 in retrospective validation cohorts; 400 eligible patients were enrolled in the prospective validation cohort between July 7, 2023 and September 15, 2023. The sensitivity of PUCAS ranged from 0.922 (95% CI: 0.811-0.978) to 1.000 (0.782-1.000) in retrospective validation cohorts, and was 0.896 (0.837-0.939) in prospective validation cohort. The PUCAS model also exhibited a good performance in detecting malignancy within atypical urothelial cells cases, with a sensitivity of over 0.84. In the recurrence detection scenario, PUCAS could reduce 57.5% of endoscopy use with a negative predictive value of 96.4%.</p><p><strong>Interpretation: </strong>PUCAS may help to improve the sensitivity of urine cytology, reduce misdiagnoses of UC, avoid unnecessary endoscopy, and reduce the clinical burden in resource-limited areas. The further validation in other countries is needed.</p><p><strong>Funding: </strong>National Natural Science Foundation of China; Key Program of the National Natural Science Foundation of China; the National Science Foundation for Distinguished Young Scholars; the Science and Technology Planning Project of Guangdong Province; the National Key Research and Development Programme of China; Guangdong Provincial Clinical Research Centre for Urological Diseases.</p>","PeriodicalId":11393,"journal":{"name":"EClinicalMedicine","volume":null,"pages":null},"PeriodicalIF":9.6000,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11056596/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EClinicalMedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.eclinm.2024.102566","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Urine cytology is an important non-invasive examination for urothelial carcinoma (UC) diagnosis and follow-up. We aimed to explore whether artificial intelligence (AI) can enhance the sensitivity of urine cytology and help avoid unnecessary endoscopy.

Methods: In this multicentre diagnostic study, consecutive patients who underwent liquid-based urine cytology examinations at four hospitals in China were included for model development and validation. Patients who declined surgery and lacked associated histopathology results, those diagnosed with rare subtype tumours of the urinary tract, or had low-quality images were excluded from the study. All liquid-based cytology slides were scanned into whole-slide images (WSIs) at 40 × magnification and the WSI-labels were derived from the corresponding histopathology results. The Precision Urine Cytology AI Solution (PUCAS) was composed of three distinct stages (patch extraction, features extraction, and classification diagnosis) and was trained to identify important WSI features associated with UC diagnosis. The diagnostic sensitivity was mainly used to validate the performance of PUCAS in retrospective and prospective validation cohorts. This study is registered with the ChiCTR, ChiCTR2300073192.

Findings: Between January 1, 2018 and October 31, 2022, 2641 patients were retrospectively recruited in the training cohort, and 2335 in retrospective validation cohorts; 400 eligible patients were enrolled in the prospective validation cohort between July 7, 2023 and September 15, 2023. The sensitivity of PUCAS ranged from 0.922 (95% CI: 0.811-0.978) to 1.000 (0.782-1.000) in retrospective validation cohorts, and was 0.896 (0.837-0.939) in prospective validation cohort. The PUCAS model also exhibited a good performance in detecting malignancy within atypical urothelial cells cases, with a sensitivity of over 0.84. In the recurrence detection scenario, PUCAS could reduce 57.5% of endoscopy use with a negative predictive value of 96.4%.

Interpretation: PUCAS may help to improve the sensitivity of urine cytology, reduce misdiagnoses of UC, avoid unnecessary endoscopy, and reduce the clinical burden in resource-limited areas. The further validation in other countries is needed.

Funding: National Natural Science Foundation of China; Key Program of the National Natural Science Foundation of China; the National Science Foundation for Distinguished Young Scholars; the Science and Technology Planning Project of Guangdong Province; the National Key Research and Development Programme of China; Guangdong Provincial Clinical Research Centre for Urological Diseases.

利用尿液细胞学图像检测尿路上皮癌的人工智能模型的开发与验证:一项具有前瞻性验证的多中心诊断研究。
背景:尿液细胞学检查是诊断和随访尿路上皮癌(UC)的一项重要无创检查。我们旨在探讨人工智能(AI)能否提高尿液细胞学检查的灵敏度,并帮助避免不必要的内窥镜检查:在这项多中心诊断研究中,我们纳入了在中国四家医院接受液基尿液细胞学检查的连续患者,用于模型的开发和验证。拒绝手术且缺乏相关组织病理学结果的患者、被诊断为尿路罕见亚型肿瘤的患者或图像质量较低的患者不在研究范围内。所有液基细胞学切片均以 40 倍放大率扫描成全切片图像(WSI),WSI 标签则来自相应的组织病理学结果。精确尿液细胞学人工智能解决方案(PUCAS)由三个不同的阶段组成(斑块提取、特征提取和分类诊断),并经过训练以识别与 UC 诊断相关的重要 WSI 特征。诊断灵敏度主要用于在回顾性和前瞻性验证队列中验证 PUCAS 的性能。本研究已在 ChiCTR 注册,ChiCTR2300073192.研究结果:2018年1月1日至2022年10月31日期间,培训队列回顾性招募了2641名患者,回顾性验证队列招募了2335名患者;2023年7月7日至2023年9月15日期间,前瞻性验证队列招募了400名符合条件的患者。在回顾性验证队列中,PUCAS 的灵敏度为 0.922(95% CI:0.811-0.978)至 1.000(0.782-1.000),在前瞻性验证队列中为 0.896(0.837-0.939)。PUCAS 模型在检测非典型尿路上皮细胞病例中的恶性程度方面也表现出色,灵敏度超过 0.84。在检测复发的情况下,PUCAS 可以减少 57.5% 的内镜检查,其阴性预测值为 96.4%:PUCAS可能有助于提高尿液细胞学检查的灵敏度,减少UC的误诊,避免不必要的内镜检查,减轻资源有限地区的临床负担。还需要在其他国家进一步验证:国家自然科学基金、国家自然科学基金重点项目、国家杰出青年科学基金、广东省科技计划项目、国家重点研发计划、广东省泌尿疾病临床研究中心。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
EClinicalMedicine
EClinicalMedicine Medicine-Medicine (all)
CiteScore
18.90
自引率
1.30%
发文量
506
审稿时长
22 days
期刊介绍: eClinicalMedicine is a gold open-access clinical journal designed to support frontline health professionals in addressing the complex and rapid health transitions affecting societies globally. The journal aims to assist practitioners in overcoming healthcare challenges across diverse communities, spanning diagnosis, treatment, prevention, and health promotion. Integrating disciplines from various specialties and life stages, it seeks to enhance health systems as fundamental institutions within societies. With a forward-thinking approach, eClinicalMedicine aims to redefine the future of healthcare.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信